Importantly, in addition to the MDS‐associated cytogenetics, mutations in chromatin modifiers (ASXL1, BCOR, EZH2), splicing‐cohesion complex genes (SF3B1, SRSF2, U2AF1, ZRSR2, STAG2) are significantly associated with AML progressing from MDS,13, 14 and are considered crucial for defining AML‐MDS related (AML‐MR). This evidence concerns the gene SRSF2 and myelodysplastic syndrome.